uՏ`wuv̌Ɛт̃f[^łB




[ _@ ]


1. Kubo T., Ochi Y., Baba Y., Hirota T., Tanioka K., Yamasaki N., Yoshimitsu M., Higuchi K., Takenaka T., Nakajima K., Togawa T., Tsukimura T., Sano S., Tei C., Sakuraba H., Kitaoka H.: Prevalence and clinical features of Fabry disease in Japanese male patients with diagnosis of hypertrophic cardiomyopathy. J. Cardiol., 69: 302-307, 2017.

2. Kodama T., Tsukimura T., Kawashima I., Sato A., Sakuraba H., Togawa T.: Differences in cleavage of globotriaosylceramide and its derivatives accumulated in organs of young Fabry mice following enzyme replacement therapy. Mol. Genet. Metab., 120: 116-120, 2017.

3. Ogawa Y., Kaizu K., Yanagi Y., Takada S., Sakuraba H., Oishi K.: FcRγ-dependent immune activation initiates astrogliosis during the asymptomatic phase of Sandhoff disease model mice. Sci. Rep, 7: 40518, 2017.

4. Ogawa Y., Kaizu K, Yanagi Y., Takada S., Sakuraba H., Oishi K.: Abnormal differentiation of Sandhoff disease model mouse-derived multipotent stem cells toward a neural lineage. PLOS ONE. , 12: e0178978, 2017.

5. Sakuraba H., Togawa T., Tsukimura T., Kato H.: Plasma lyso-Gb3: a biomarker for monitoring fabry patients during enzyme replacement therapy. Clin. Exp. Nephrol., doi: 10.1007/s10157-017-1525-3, 2017